Literature DB >> 18046443

T-cell lymphomas in T-cell-specific Pten-deficient mice originate in the thymus.

T J Hagenbeek1, H Spits.   

Abstract

Phosphatase and tensin homolog deleted on chromosome 10 (Pten) is a tumor suppressor protein whose loss of lipid phosphatase activity is associated with lymphomagenesis. We made use of the Cre-loxP system to delete Pten expression in Lck- or CD4-expressing T-lineage cells. Mice initially showed modest thymic hyperplasia and subsequently developed expanding and infiltrating T-cell lymphomas, leading to a premature death within 5 to 23 weeks. Frequently, all thymocyte and peripheral T-cell populations displayed phenotypes characteristic for immature developing thymocyte precursors and shared elevated levels of clonally rearranged T-cell receptor (TCR) beta chains. In concert, CD2, CD5, CD3epsilon and CD44, proteins associated with increased expression and signaling capacity of both the immature pre-TCR and the mature alphabetaTCR, were more abundantly expressed, reflecting a constitutive state of activation. Although most T-cell lymphomas had acquired the capability to infiltrate the periphery, not all populations left the thymus and expanded clonally exclusively in the thymus. In line with this, only transplantation of thymocytes with infiltrating capacity gave rise to T-cell lymphoma in immunodeficient recipients. These results indicate that T-cell-specific Pten deletion during various stages of thymocyte development gives rise to clonally expanding T-cell lymphomas that frequently infiltrate the periphery, but originate in the thymus.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18046443     DOI: 10.1038/sj.leu.2405056

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  38 in total

Review 1.  Molecular Insights Into Pathogenesis of Peripheral T Cell Lymphoma: a Review.

Authors:  Waseem Lone; Aisha Alkhiniji; Jayadev Manikkam Umakanthan; Javeed Iqbal
Journal:  Curr Hematol Malig Rep       Date:  2018-08       Impact factor: 3.952

2.  Combined deficiency for MAP kinase-interacting kinase 1 and 2 (Mnk1 and Mnk2) delays tumor development.

Authors:  Takeshi Ueda; Masato Sasaki; Andrew J Elia; Iok In Christine Chio; Koichi Hamada; Rikiro Fukunaga; Tak W Mak
Journal:  Proc Natl Acad Sci U S A       Date:  2010-08-02       Impact factor: 11.205

3.  Analysis of the expression level and methylation of tumor protein p53, phosphatase and tensin homolog and mutS homolog 2 in N-methyl-N-nitrosourea-induced thymic lymphoma in C57BL/6 mice.

Authors:  Xueyun Huo; Zhenkun Li; Shuangyue Zhang; Changlong Li; Meng Guo; Jing Lu; Jianyi Lv; Xiaoyan Du; Zhenwen Chen
Journal:  Oncol Lett       Date:  2017-08-04       Impact factor: 2.967

Review 4.  Metabolism, migration and memory in cytotoxic T cells.

Authors:  David Finlay; Doreen A Cantrell
Journal:  Nat Rev Immunol       Date:  2011-01-14       Impact factor: 53.106

5.  HSF1-Mediated Control of Cellular Energy Metabolism and mTORC1 Activation Drive Acute T-Cell Lymphoblastic Leukemia Progression.

Authors:  Binnur Eroglu; Junfeng Pang; Xiongjie Jin; Caixia Xi; Demetrius Moskophidis; Nahid F Mivechi
Journal:  Mol Cancer Res       Date:  2019-11-19       Impact factor: 5.852

6.  Therapeutic antibody targeting of individual Notch receptors.

Authors:  Yan Wu; Carol Cain-Hom; Lisa Choy; Thijs J Hagenbeek; Gladys P de Leon; Yongmei Chen; David Finkle; Rayna Venook; Xiumin Wu; John Ridgway; Dorreyah Schahin-Reed; Graham J Dow; Amy Shelton; Scott Stawicki; Ryan J Watts; Jeff Zhang; Robert Choy; Peter Howard; Lisa Kadyk; Minhong Yan; Jiping Zha; Christopher A Callahan; Sarah G Hymowitz; Christian W Siebel
Journal:  Nature       Date:  2010-04-15       Impact factor: 49.962

7.  L-type amino-acid transporter 1 (LAT1): a therapeutic target supporting growth and survival of T-cell lymphoblastic lymphoma/T-cell acute lymphoblastic leukemia.

Authors:  C Rosilio; M Nebout; V Imbert; E Griessinger; Z Neffati; J Benadiba; T Hagenbeek; H Spits; J Reverso; D Ambrosetti; J-F Michiels; B Bailly-Maitre; H Endou; M F Wempe; J-F Peyron
Journal:  Leukemia       Date:  2014-12-08       Impact factor: 11.528

8.  The role of the PI3K-AKT kinase pathway in T-cell development beyond the beta checkpoint.

Authors:  Ling Xue; Leslie Chiang; Chulho Kang; Astar Winoto
Journal:  Eur J Immunol       Date:  2008-11       Impact factor: 5.532

Review 9.  Oncogenic PTEN functions and models in T-cell malignancies.

Authors:  M Tesio; A Trinquand; E Macintyre; V Asnafi
Journal:  Oncogene       Date:  2015-11-30       Impact factor: 9.867

10.  Phosphoinositide-dependent kinase 1 controls migration and malignant transformation but not cell growth and proliferation in PTEN-null lymphocytes.

Authors:  David K Finlay; Linda V Sinclair; Carmen Feijoo; Caryll M Waugh; Thijs J Hagenbeek; Hergen Spits; Doreen A Cantrell
Journal:  J Exp Med       Date:  2009-10-05       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.